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Spinal and bulbar muscular atrophy (SBMA) is caused by expression of a polyglutamine
(polyQ)-expanded androgen receptor (AR). The inefficient nuclear proteasomal
degradation of the mutant AR results in the formation of nuclear inclusions containing
amino-terminal fragments of the mutant AR. PA28γ (also referred to as REGγ) is
a nuclear 11S-proteasomal activator with limited proteasome activation capabilities
compared to its cytoplasmic 11S (PA28α, PA28β) counterparts. To clarify the role of
REGγ in polyQ-expanded AR metabolism, we carried out genetic and biochemical
studies in cell models of SBMA. Overexpression of REGγ in a PC12 cell model of
SBMA increased polyQ-expanded AR aggregation and contributed to polyQ-expanded
AR toxicity in the presence of dihydrotestosterone (DHT). These effects of REGγ were
independent of its association with the proteasome and may be due, in part, to the
decreased binding of polyQ-expanded AR by the E3 ubiquitin-ligase MDM2. Unlike its
effects in PC12 cells, REGγ overexpression rescued transgenic SBMA motor neurons
from DHT-induced toxicity in a proteasome binding-dependent manner, suggesting
that the degradation of a specific 11S proteasome substrate or substrates promotes
motor neuron viability. One potential substrate that we found to play a role in mutant
AR toxicity is the splicing factor SC35. These studies reveal that, depending on
the cellular context, two biological roles for REGγ impact cell viability in the face of
polyQ-expanded AR; a proteasome binding-independent mechanism directly promotes
mutant AR aggregation while a proteasome binding-dependent mechanism promotes
cell viability. The balance between these functions likely determines REGγ effects on
polyQ-expanded AR-expressing cells.
Keywords: proteasome, PA28, androgen receptor, polyglutamine, neurodegeneration
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA) is an X-linked neurodegenerative disease that is
caused by expansion of a polyglutamine (polyQ)-encoding CAG repeat in exon 1 of the androgen
receptor (AR) gene (La Spada et al., 1991). The disease is characterized by muscle atrophy and the
loss of motor neurons from the spinal cord and brainstem (Sobue et al., 1989). Moreover, as in
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other polyQ diseases, remaining motor neurons are marked by
the presence of neuronal intranuclear inclusions (NII) of the
mutant polyQ-expanded protein (Li et al., 1998). In SBMA, NII
are comprised of the amino-terminal portion of expanded AR; in
addition, retention of the mutant AR in the cytoplasm prevents
its proteolytic cleavage (Montie et al., 2009), suggesting that the
mutant AR is aberrantly cleaved within the nucleus (Li et al.,
1998; Li M. et al., 2007).
Model systems of SBMA reveal the requirement for both
androgen (testosterone or dihydrotestosterone—DHT) binding
(Katsuno et al., 2002; Takeyama et al., 2002; Walcott and Merry,
2002; Chevalier-Larsen et al., 2004) and nuclear entry of the AR
for disease (Takeyama et al., 2002; Montie et al., 2009; Nedelsky
et al., 2010). Moreover, while nuclear localization of the mutant
AR is necessary, it is not sufficient, as nuclear AR still requires
hormone binding to cause AR aggregation and toxicity (Montie
et al., 2009; Nedelsky et al., 2010). The nucleus of the cell
differs from the cytoplasm in its degradation capabilities, lacking
lysosomal and autophagic degradation machineries. Thus,
proteins that are not exported to the cytoplasm for degradation
must be degraded by nuclear proteasomes. This difference may
explain the requirement for AR nuclear localization in its toxicity,
as inhibition of autophagy in cells expressing cytoplasmically
localized mutant AR removes the protection that this localization
otherwise affords (Montie and Merry, 2009; Montie et al., 2009).
The limited degradation machinery within the nucleus could
expose this compartment to higher levels of cellular stress in the
presence of mutant AR.
Ubiquitin-proteasome system (UPS) function is central to
the molecular pathogenesis of many neurodegenerative diseases.
For example, both ubiquitin and components of the UPS are
found within nuclear inclusions in SBMA cell andmousemodels,
as well as in patient autopsy material, implicating deficits in
expanded AR proteasomal degradation both in vitro and in vivo
(Li et al., 1998; Stenoien et al., 1999; Abel et al., 2001; Bailey et al.,
2002).
The proteasome is a dynamic protein complex that contains
a 20S core, which is composed of two outer α rings and
two inner catalytic β rings, each composed of seven subunits
(α7, β7, β7, α7; Orlowski and Wilk, 2003). The three proteolytic
active sites present in the inner β rings hydrolyze peptide
bonds with chymotrypsin-like (CT-L), trypsin-like (T-L), and
peptidylglutamyl-preferring hydrolytic (PGPH) or caspase-like
(C-L) activities. The 20S proteasomal core is catalytically
activated by the binding of a proteasomal activator to its
outer α rings. The known proteasomal activators include the
19S, 11S and PA200 activators, which can bind to the 20S
proteasome core in multiple combinations on either end,
forming both homotypic and hybrid proteasomes (Tanahashi
et al., 2000). The 11S proteasomal activator PA28 (REG) is
found as three distinct isoforms, REGα, β and γ, which bind
to and activate the proteasome in an ATP- and ubiquitin-
independent manner (Gray et al., 1994). REGα and REGβ, which
form heteroheptameric rings (α3, β4) and activate all three
proteolytic activities of the 20S proteasome, are confined to the
cytoplasm. In contrast, REGγ, which is largely confined to the
nucleus, binds to the 20S core as a homoheptameric ring and
primarily activates only its T-L activity (Realini et al., 1997).
The limited proteasome-activating function of REGγ is largely
conferred by lysine 188, since amutation of this lysine to an acidic
amino acid (K188E, K188D) alters its function to promote the
activation of all three proteasomal catalytic activities (Li et al.,
2001).
The function of REGγ as an 11S proteasomal activator plays
a role in a variety of cellular processes. For example, REGγ
promotes the degradation of the cell cycle regulatory proteins
p21WAF/CIP1, p16INK4A, p19ARF and oncogene SRC3 in an ATP-
and ubiquitin-independent manner, thereby affecting cell cycle
regulation and cell proliferation (Li et al., 2006; Li X. et al.,
2007; Chen et al., 2007). Gene ablation of REGγ in a mouse
model results in significantly reduced body size and REGγ-
deficient embryonic fibroblasts fail to enter S phase of the cell
cycle (Murata et al., 1999; Barton et al., 2004), further implicating
REGγ in cell proliferation and cell cycle regulation. Other nuclear
targets of REGγ include SIRT1 and DBC1 (Dong et al., 2013;
Magni et al., 2014). In addition, while other REGγ substrates are
unknown, REGγ was also shown to modulate the homeostasis
of several distinct nuclear bodies, including Cajal bodies (Cioce
et al., 2006) and nuclear speckles (Baldin et al., 2008). An
additional role for REGγ that is independent of its binding
to the 20S proteasomal core involves its direct stimulation
of MDM2-dependent polyubiquitination of p53, resulting in
p53 degradation by the 26S proteasome, thereby promoting cell
survival (Zhang and Zhang, 2008).
Here we present data demonstrating that REGγ influences
polyQ-expanded AR aggregation and toxicity in SBMA cell and
motor neuron models through distinct proteasome binding-
dependent and -independent mechanisms. We discovered
that REGγ overexpression increases ARQ112 aggregation in
PC12 cells in a proteasome activating- and binding-independent
manner. REGγ interacts with expanded AR, decreasing its
polyubiquitination, possibly by decreasing its interaction with
the E3 ligase MDM2. REGγ overexpression also failed to
protect PC12 cells from DHT-dependent AR toxicity. On
the other hand, REGγ overexpression rescued ARQ112-
expressing motor neurons from DHT-dependent cell death
in a proteasome binding-dependent manner. Evaluation of
several known and candidate REGγ substrates revealed that one
candidate REGγ substrate, RNA splicing factor SC35 (Srsf2;
Fu and Maniatis, 1992; Shepard and Hertel, 2009), is elevated
upon polyQ-expanded AR expression, further elevated upon
DHT treatment, and is reduced by REGγ overexpression.
Moreover, reducing SC35 levels proved to be protective in
both cell models of SBMA. Altogether, our results suggest that
REGγ may play a neuroprotective role in cell types in which
its proteasome-activating functions supersede its proteasome
binding-independent functions.
MATERIALS AND METHODS
Cell Culture and Reagents
Tet-On PC12 cells expressing either ARQ112 or ARQ10,
were previously created in our laboratory (Walcott and
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Merry, 2002). Cells were maintained in normal growth media
(Dulbecco’s modified Eagle’s medium with 10% heat-inactivated
horse serum, 5% heat-inactivated fetal bovine serum, 2 mM
L-glutamine, 100 units/ml penicillin/streptomycin, 200 µg/ml
hygromycin (Invitrogen, Carlsbad, CA, USA), 100 µg/ml G418
(Mediatech, Manassas, VA, USA) at 37◦C, 10% CO2). All
experiments were performed utilizing charcoal-stripped serum.
Cells were induced with 500 ng/ml doxycycline (Dox; Clontech)
to express equivalent levels of AR and treated with 10 nM DHT
(Sigma Aldrich). Stable REGγ transformants were selected with
puromycin (2 µg/ml; Invitrogen, Inc.). Proteasome inhibitor
epoxomycin (Sigma Aldrich) was used at 500 nM concentration.
Plasmids and Site Directed Mutagenesis
FLAG-REGγ pcDNA3.1+plasmid (provided by
Dr. Martin Rechsteiner, University of Utah). Site-directed
mutagenesis (Quick Change II XL, Stratagene) was
performed to mutate FLAG- REGγ into both REGγP245Y
and REGγK188E. Mutations were confirmed by sequence
analysis.
REGγ PC12 Cell Lines
Stable transfections of Tet-On PC12 ARQ112 and ARQ10 cells
were performed utilizing a calcium phosphate transfection
protocol. FLAG-REGγ or FLAG-REGγP245Y plasmids
were co-transfected with puromycin pBABE plasmid (kindly
provided by Dr. Karen Knudsen, Thomas Jefferson University)
at a 4:1 ratio, respectively. Single colonies were isolated,
expanded, and screened for overexpressed REGγ using
PSME3 antibody (BD Transduction Laboratories). Cells
were maintained as stated above and media was supplemented
with puromycin.
Western Blot Analysis
PC12 cells and dissociated spinal cord cultures were lysed
in 0.5% Triton-0.5% DOC lysis buffer and sonicated using
a Branson cup sonifier. A DC protein assay (Bio Rad, Inc.)
was performed to determine protein concentration. Protein
lysates were electrophoresed by SDS-PAGE and transferred
to a 0.45 µm PVDF (Immobilon-P) membrane. Western
hybridization was performed using the following antibodies:
[(AR(H280), AR(N20), AR(441) Santa Cruz Biotechnology),
GAPDH (Fitzgerald Industries International)] (1:1000),
[MDM2(SMP14); γ-tubulin (1:10,000) (Sigma Aldrich); REGγ
(PSME3)] (1:2000) (BD Transduction Laboratories); FLAG
(1:500) (Affinity BioReagents); SC35 (1:500) (Euromedex).
Detection was carried out using ECL substrate (Pierce).
Filter trap analysis was carried out as previously described
(Bailey et al., 2002). Western analysis was performed using
a standard protocol for antibody ARH280 (Santa Cruz
Biotechnology).
Immunofluorescence
PC12 cells and dissociated spinal cord cultures were fixed
with 4% paraformaldehyde for 20 min, washed in PBS,
permeabilized with 0.3% Triton X-100 for 15 min, blocked
in 2% goat serum (Jackson ImmunoResearch, West Grove,
PA, USA) for 20 min and incubated with primary antibody
diluted in 1.5% goat serum for 1 h. Cells were washed in
PBS and incubated with secondary antibody (FITC- or Texas
Red-conjugated; Jackson ImmunoResearch, West Grove, PA,
USA) for 30 min, washed with PBS, incubated in Hoechst
(2 µg/ml), washed in PBS and mounted in Vectashield
(Vector Laboratories, Burlingame, CA, USA). Fluorescence
was visualized with a Leica (Leica Microsystems GmbH,
Wetzlar, Germany) microscope and pictures were taken
with a Leica camera and compiled with IP Lab software
(BD Biosciences, Rockville, MD, USA). Antibodies utilized
included the following: [AR(N20), AR(H280)] (1:100),
p16(M-156) (1:50) (Santa Cruz Biotechnology); PSME3 (1:100)
(BD Transduction Laboratories); FLAG (1:100) (Affinity
BioReagents); SMI32 (1:1000) (Sternberger Monoclonal,
Baltimore, MD, USA).
Co-Immunoprecipitation Assay
PC12 cells were either treated with Dox (500 ng/ml) for
48 h and DHT (10 nM) in the presence or absence of
epoxomycin (500 nM) for the last 12 h or with Dox
(500 ng/ml) and DHT (10 nM) for 72 h with or without
epoxomycin (500 nM) for the last 12 h. Controls consisted
of PC12 ARQ112 cells inducibly expressing FLAG-REGγ or
FLAG-REGγP245Y that were not treated with Dox or DHT,
but treated with epoxomycin for 12 h. Cells were harvested
in NP-40 lysis buffer (0.15 M NaCl, 50 mM NaF, 50 mM
Tris-HCl (pH 7.5), 0.5% NP-40, and protease inhibitors),
sonicated and protein concentration determined. Cell lysates
(250 µg) were precleared with magnetic Protein G Dynabeads
(Invitrogen) for 1 h at room temperature. Precleared lysates
were incubated with AR(H280) antibody (0.5 µg) overnight at
4◦C. Protein G Dynabeads were incubated with lysate/antibody
for 30 min at room temperature, unbound lysate was removed
and the beads were washed four times with NP-40 lysis buffer.
Product was eluted with 2× Laemmli buffer and electrophoresed
by SDS-PAGE, transferred to PVDF and Western analysis
performed.
Adenovirus Construction, Titration and
Purification
FLAG-REGγ and FLAG-REGγK188E adenoviruses (replication
incompetent (deltaE1/E3) human adenoviral type 5 genome)
were constructed utilizing BD Adeno-XTM Expression
System 1 (BD Biosciences). In brief, the pShuttle2 plasmid
(BD Biosciences) and the FLAG- REGγ plasmids were digested
with NheI and NotI restriction enzymes and then ligated to each
other. The pShuttle2/FLAG-REGγ plasmid and BD Adeno-X
Viral DNA (provided) were then cut with I-CeuI and PI-SceI
restriction enzymes and ligated to each other. The resulting BD
Adeno-X Viral plasmid containing FLAG-REGγ was sequenced
to ensure proper ligation and then purified and digested with
PacI restriction enzyme in order to linearize the plasmid.
The PacI digested plasmids were transfected into low passage
HEK293T cells and then freeze/thawed to release adenovirus.
Adenoviruses were purified utilizing the VirabindTM Adenovirus
Miniprep kit (Cell Biolabs, Inc., San Diego, CA, USA) and then
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titered using the QuickTiterTM Adenovirus Immunoassay Kit
(Cell Biolabs, Inc., San Diego, CA, USA) according to published
protocols.
Adenovirus Overexpression Assay
PC12 ARQ112 cells were plated at 5 × 105 cells/well in a
6-well dish and then infected with the following adenoviruses
at multiplicity of infection (MOI) 100: FLAG-REGγ, FLAG-
REGγK188E, LacZ. Cells were treated with 50 µM DHT and
500 ng/ml Dox for 72 h and then harvested for protein or
immunostained as described above. Percent cells infected by
FLAG-REGγ and FLAG-REGγKE were measured by calculating
the number of FLAG-positive cells/total number of cells. LacZ
viral infection was determined by performing an X-gal stain.
Cells were counted and percent of cells with nuclear inclusions
was calculated. Statistical analysis was carried out as described
below.
siRNA Assay
For REGγ knockdown studies: PC12 ARQ112 cell pellets
(4 × 106 cells) were resuspended in 100 µl of Nucleofector
solution V (Amaxar) (Lonza Cologne GmbH) with
50 pmol REGγsiRNA (ON-TARGETplus SMART pool rat
PSME3), 50 pmol Non-Targeting siRNA (ON-TARGETplus
Non-Targeting siRNA #1) (Dharmacon) or 2 µg GFP
plasmid (Amaxa). Cells were electrophoresed using the
Amaxa Nucleofector System (program U-029) and then
replated in 6-well and 24-well dishes. At 72 h post
nucleofection, cells were treated with Dox and DHT for
48 h. Cells were harvested at 120 h total and either lysed
in Triton DOC lysis buffer and run on SDS-PAGE gels or
immunostained. Percentage of siRNA protein knockdown
was determined by densitometry. Cells were counted and
percent of cells with nuclear inclusions was calculated.
Statistical analysis was carried out using the Student’s
t-test.
Transient Transfection
PC12 ARQ112 cells were electroporated with the Amaxar
Nucleofectorr System (Lonza Cologne GmbH) as described
above with the following plasmids: FLAG-REGγ, FLAG-
REGγP245Y, or GFP. Twenty-four hours post-transfection, cells
were treated with Dox (500 ng/ml) and DHT (10 nM) for
72 h. Cells were then either harvested for biochemical analysis
(Triton-DOC lysis buffer) or immunostained as described
above.
GST-TUBE (Tandem Ubiquitin Binding
Entity) Assay
Cells were grown in 100 mm dishes and induced with Dox
(500 ng/ml) for 60 h and treated with DHT (10 nM) and
epoxomycin (500 nM) for the last 12 h. Cells were lysed on
the dish in tandem ubiquitin binding entity (TUBE) lysis buffer
(20 nMNa2HPO4, 20 nMNaH2PO4 (pH 7.2), 50mMNaF, 5mM
tetra-sodium pyrophosphate, 10 nM β-glycerophosphate, 2 mM
EDTA, 1 mMDTT, 1% NP-40) supplemented with fresh N-ethyl
maleimide (NEM; 10 mM), and protease inhibitors and then
40 µl of GST-TUBE2 (Lifesensors, Inc., Malvern, PA, USA) was
added. Cells were incubated on ice for 15 mins and then clarified
(12,000 rpm for 10 min). A DC protein assay was performed
to determine protein concentration. Glutathione (GST) affinity
resin (GE Healthcare, Inc.; 100 µl) was equilibrated according
to the provided protocol. GST resin was added to the cell
lysate/TUBEs (2.5 mg protein) and incubated at 4◦C for 4 h.
GST-resin was collected by centrifugation (1000× g, 4◦C)
for 5 min, unbound sample was removed and resins washed
three times with TBST. Product was eluted in 2× Laemmli
buffer and loaded on a 10% SDS-PAGE gel for electrophoresis
and transferred to 0.45 mM PVDF (Immobilon-P). Western
hybridization was performed using the following antibodies:
AR(441) (1:500) (Santa Cruz Biotechnology) and Ubiquitin
(1:1000) (Dako).
PC12 Cell Toxicity Assay
FLAG-REGγ-expressing PC12 cells, inducible for ARQ112 or
ARQ10, were treated with 500 ng/ml Dox to express equivalent
AR levels and then treated in the presence or absence of
10 nM DHT for 12 days. Cells were harvested and stained
with trypan blue. Two hundred cells were counted per
cell type/condition in triplicate. The percentage of trypan
blue-positive cells was calculated and significance determined as
described below.
Construction of AAV Viruses
Adeno-associated viruses (AAV; type 1) were constructed by
the following protocol: FLAG-RE REGγ pcDNA3.1 plasmids
were cut with HindIII and XhoI restriction enzymes (Fisher
Scientific) and the AAV-Cis plasmid (AM/CBA-pl-WPRE-bGH
containing a chicken β-actin promoter and CMV enhancer)
was cut with BamHI and XhoI restriction enzymes (Fisher
Scientific); the two plasmids were ligated to form the FLAG-
REGγ AAV-Cis plasmid. In addition, the pcDNATM6.2-GW/
EmGFP-miR plasmid, containing scrambled miRNA or miRNA
sequences against SC35 (construction of these plasmids outlined
below) was cut with XhoI and partially cut with DraI, while
the AAV-Cis plasmid was cut with EcoRI and EcoRV. Both
plasmids were treated with Klenow to blunt the ends and ligated
together to form the scrambled AAV-, SC35 miRNA #24 AAV-,
SC35 miRNA #27 AAV-Cis plasmids. Low passage HEK293T
cells were plated and transfected with the FLAG-REGγCis, Trans
(H21), and Adenovirus-associated Helper (δ6) plasmids using
calcium phosphate. At three–5 days post-transfection, cells were
harvested, lysed in PBS, freeze/thawed three times in order to
obtain AAV viral stocks and then filtered. The volume of virus
(HEK293T cell lysate) to achieve maximum AAV infection of
motor neurons dissociated spinal cord cultures was determined
by immunostaining for the protein of interest 5 days post-
infection.
Dissociated Spinal Cord Cultures
Dissociated spinal cord cultures were established according to
published literature (Roy et al., 1998; Montie et al., 2009).
Spinal cord cultures derived from transgenic ARQ112 mice
were dissected on ice from 13.5-day-old embryos. Genotyping
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 May 2017 | Volume 10 | Article 159
Yersak et al. REGγ in SBMA
was carried out from a tail biopsy. Transgenic ARQ112 spinal
cords were pooled, plated for culture and incubated for
3 weeks in conditioned media [MEM, 3% charcoal-stripped
horse serum, 35 mM NaHCO3, 0.5% dextrose, 1% N3, 10 nM
2.5 S NGF (added after conditioning)] from 13.5-day-old
non-transgenic brain. Motor neurons were identified in these
mixed spinal cord cultures by staining with neurofilament
heavy chain (SMI32) antibody and morphology. Three weeks
after culture initiation, motor neurons were infected with the
following AAV-viruses: EGFP, FLAG-REGγ, FLAG-REGγKE,
FLAG-REGγP245Y, scrambled miRNA, or miRNAs against
SC35 (#24 and #27). Five days following infection, motor
neurons were treated with EtOH or 10 µM DHT for an
additional 7 days. The work described here was carried
out in strict accordance with the recommendations of The
Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health, with approval by the
Institutional Animal Care and Use Committee of Thomas
Jefferson University.
Creation of PC12 Cell Lines with
Knockdown of SC35
Two pre-designed oligos (forward and reverse for each,
Mmi519524 and Mmi519527) containing miRNA sequences
against SC35, as well as scrambled, control sequences,
were purchased from Invitrogen, annealed and cloned into
pcDNATM6.2-GW/ EmGFP-miR (BLOCK-iTTM), containing
a blasticidin resistance gene, according to the manufacturer’s
recommendations. Inducible PC12 cells (ARQ112) were stably
transfected with these plasmids. Twenty-four hours post-
transfection, cells were selected with (15 ng/mL) blasticidin.
After 2 weeks in culture, 100% of the cells expressed EmGFP.
Cells were treated with EtOH or 10 nM DHT for 12 days. At the
end of the treatment, cells were harvested and stained for trypan
blue. Two hundred cells were counted per cell type/condition
in triplicate. The percentage of trypan blue-positive cells
was calculated and significance was determined as described
below.
Statistical Analysis
Statistical analysis was carried out using either SigmaStat
or Excel. For single factor analysis of variance (ANOVA),
post hoc Bonferroni-corrected Student’s t-test was used to
determine statistically significant differences. For two factor
ANOVA, post hoc Tukey HSD was used to determine statistically
significant differences. For single sample analysis with two
conditions, Student’s t-test was used after determining sample
variance with the F statistic.
RESULTS
REGγ Is Present in ARQ112 Nuclear
Inclusions
Numerous studies have demonstrated that components of the
UPS system are present within nuclear inclusions in cell and
FIGURE 1 | REGγ colocalizes with ARQ112 in inclusion bodies in
PC12 cells. Immunofluorescence of PC12 ARQ112 cells induced with
doxycycline (Dox) and treated with dihydrotestosterone (DHT) for 48 h. Cells
were stained with androgen receptor (AR; H280) and REGγ antibodies.
Hoechst staining was carried out to detect nuclei. Arrow indicates a cell
positive for AR nuclear inclusions that co-localize with REGγ; this cell is
magnified in the inset. Scale bar represents 5 µm.
animal models of SBMA and tissue of affected SBMA patients (Li
et al., 1998; Stenoien et al., 1999; Abel et al., 2001; Walcott and
Merry, 2002); we therefore wished to determine whether REGγ
co-localizes with hormone-induced ARQ112 nuclear inclusions
in this cell model of SBMA. We observed REGγ both in a
diffuse nuclear distribution and co-localized with a portion of AR
nuclear inclusions (Figure 1).
Both REGγ and REGγK188E Isoforms
Cause a Substantial Increase in the
Frequency of Cells Containing
ARQ112 Nuclear Inclusion Bodies
The presence of REGγ in AR nuclear inclusions suggests that
nuclear REGγ-capped proteasomes may play a role in the
inefficient degradation of mutant AR. Moreover, it has been
previously shown that REGγ is capable of activating only the
T-L activity of the 20S proteasome core, thereby limiting the
degradative capacity of nuclear 11S proteasomes (Realini et al.,
1997). However, mutation of REGγ at lysine 188 to an acidic
residue (K188E, K188D), as found in the cytoplasmic REG
homologs REGα and β (Zhu et al., 2001), allows the activation of
all three catalytic activities of the REGγ-capped 20S proteasome.
We therefore sought to investigate whether overexpression
of REGγ or REGγK188E would impact the aggregation of
expanded AR. We predicted that REGγK188E might enhance
the nuclear degradation of expanded full-length AR or expanded
AR fragments due to its REGα/β-like activation capabilities
and thereby decrease AR aggregation. The cell model that we
used to test this hypothesis is a well characterized inducible
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PC12 cell model of SBMA, in which hormone treatment of
cells expressing an AR gene with 112 CAG repeats (ARQ112)
results in the formation of nuclear inclusions comprised of
an amino-terminal AR fragment (Walcott and Merry, 2002;
FIGURE 2 | Overexpression of REGγ and REGγK188E significantly
increases the percentage of cells with ARQ112 nuclear inclusion
bodies whereas decreased expression reduces this percentage.
(A) PC12 cells expressing ARQ112 were infected with adenovirus expressing
FLAG-REGγ, FLAG-REGγK188E or LacZ at multiplicity of infection 100 (MOI
100). Cells were then treated with Dox to induce AR in the presence of DHT
for 72 h. Cells were immunostained with antibodies to the AR (N20), to FLAG
for infectivity and stained with Hoechst to reveal nuclei. The percentage of
cells with nuclear inclusions was calculated. Single factor analysis of variance
(ANOVA) with post hoc Bonferroni-corrected t-test was performed.
∗∗p < 0.01; ∗∗∗p < 0.001. The above PC12 ARQ112 cells were also
harvested at 72 h and evaluated for REGγ protein levels via Western blot
analysis. Note the overexpression of FLAG-REGγ compared to endogenous
protein levels. (B) PC12 ARQ112 cells were transfected with siRNA against
REGγ or with a non-targeting siRNA control for 72 h. Cells were then induced
with Dox and treated with DHT for 48 h. Cells were harvested after 120 h to
evaluate REGγ protein levels via Western blot analysis. Densitometry showed
77% knockdown of REGγ protein. Cells were immunostained at 120 h with
AR(N20) antibody and stained with Hoechst. The percentage of cells with
nuclear inclusions was calculated. Student’s t-test was performed. ∗∗p < 0.01.
Heine et al., 2015), as observed in SBMA patient neurons (Li
et al., 1998). Moreover, nuclear inclusions correlate well with a
subset of biochemical AR aggregates detected by SDS-agarose
gel electrophoresis (SDS-AGE; Berger et al., 2015; Heine et al.,
2015). To test our hypothesis, adenoviruses were created to
express FLAG-tagged REGγ, FLAG-REGγK188E or LacZ in
PC12 ARQ112 cells. Overexpression of both FLAG-REGγ and
FLAG-REGγK188E resulted in a substantial increase in the
frequency of cells with ARQ112 nuclear inclusions, compared to
the LacZ control (Figure 2A).
We next wanted to determine whether knockdown of
REGγ would impact expanded AR aggregation. Knockdown
of REGγ caused a significant decrease in ARQ112 inclusion
bodies, but did not eliminate them (Figure 2B). Thus, not
only did the overexpression of REGγ enhance AR aggregation,
but the knockdown of endogenous REGγ decreased AR
aggregation, suggesting a role for REGγ in the aggregation of
mutant AR.
The REGγ-Induced Increase in
ARQ112 Inclusion Bodies Does Not
Require its Binding to the 20S Proteasome
Core
One possible explanation for these results is that REGγ
heptameric rings compete with the 19S proteasomal activator,
thereby decreasing AR degradation and enhancing its
aggregation. Therefore, given that REGγ has functions that
are both proteasome binding-dependent and proteasome
binding-independent, we asked whether proteasome binding by
REGγ is required for these effects. Proline 245 was previously
shown to be required for the binding of REGγ to the 20S
proteasome α rings (Zhang et al., 1998; Zhang and Zhang,
2008). To determine whether interaction of REGγ with the
20S proteasome core is required for the observed REGγ effects
on ARQ112 aggregation, we created PC12 ARQ112 cells that
stably express either REGγ or the proteasome-binding mutant
REGγP245Y. We found that stable overexpression of both REGγ
and REGγP245Y significantly increased ARQ112 aggregation
(Figure 3A, Supplementary Figure S1), indicating that REGγ
increases expanded AR aggregation in a 20S proteasome-
binding-independent manner. Moreover, mutant REGγP245Y
had a slightly greater effect on increasing ARQ112 aggregation,
compared to wild-type REGγ, possibly due to its limited
non-proteasome binding role. The same aggregation results were
observed upon transient overexpression of both constructs (data
not shown). Neither overexpression of REGγ or of REGγP245Y
altered the steady state levels of ARQ112 (Figure 3B).
REGγ Interacts with ARQ112
With the observation that REGγ promotes AR aggregation
in a proteasome binding-independent manner, we sought
to determine the mechanism for this effect. We found
that full-length ARQ112 co-immunoprecipitated with
both endogenous and exogenous (overexpressed) REGγ
(Figures 4A,B). Moreover, treatment of cells with the
proteasome inhibitor epoxomicin enhanced the interaction of
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FIGURE 3 | Overexpression of REGγP245Y mutant significantly
increases the percentage of cells with ARQ112 nuclear inclusion
bodies. PC12 ARQ112 cells that stably overexpress either REGγ or
REGγP245Y were induced with Dox and treated with DHT for 72 h. (A) Cells
were immunostained with AR(H280) and stained with Hoechst. The number of
cells containing nuclear inclusions was determined and their percentage
calculated. Single factor ANOVA with post hoc Bonferroni-corrected t-test
was performed. ∗∗p < 0.01; ∗∗∗p < 0.001. See Supplementary Figure S1 for
additional analysis of AR aggregation. (B) Western blot analysis of same cell
populations as in (A) reveals lack of effect of REGγ or REGγP245Y
overexpression on monomeric AR levels.
REGγ with ARQ112 (Figure 4B), without changing the steady-
state levels of REGγ or AR (Figure 4B, right). We also found that
REGγP245Y co-immunoprecipitated with ARQ112 (Figure 7),
indicating that REGγ can interact with ARQ112 independently
of REGγ association with the proteasome. We did not detect an
interaction of REGγ with unexpanded ARQ10 (data not shown),
suggesting that REGγ has a limited, if any, role in normal AR
metabolism.
Both REGγ and REGγP245Y Fail to Protect
SBMA PC12 Cells from DHT-Dependent
Death
Utilizing PC12-AR-expressing cell lines that we engineered to
stably overexpress REGγ or REGγP245Y, we examined whether
overexpression of both isoforms modulated DHT-dependent cell
death. We found that ARQ112 cells stably overexpressing either
REGγ or REGγP245Y were not protected from DHT-induced
AR toxicity (Figures 5A,B), and neither of the REGγ isoforms
caused death in cells expressing unexpanded ARQ10 (Figure 5A,
data not shown).Moreover, REGγP245Y overexpression resulted
in slightly increased toxicity (Figure 5B), as observed with its
effect on AR aggregation.
FIGURE 4 | AR interacts with REGγ. (A) PC12 ARQ112 cells were
transiently transfected with FLAG-REGγ or GFP and then induced with Dox
and treated with DHT for 72 h. Lysates were immunoprecipitated with
AR(H280) antibody, separated by SDS-PAGE and protein complexes detected
by Western analysis using AR(318) and REGγ antibodies. Included controls
are no antibody and no transfection. (B) PC12 ARQ112 cells were induced
with Dox and treated with DHT for 48 h and then treated with or without
epoxomycin for an additional 12 h. (Left) AR was immunoprecipitated with
AR(H280) antibody. Included controls have no AR expression or no antibody in
the IP. Western blot analysis was carried out with AR(318), REGγ and
MDM2 antibodies to evaluate protein complexes. (Right) Whole cell extracts
(WCE) used for IP were evaluated for respective protein levels by Western blot
analysis. GAPDH was employed as a loading control.
Overexpression of REGγ and REGγP245Y
Decreases Polyubiquitination of ARQ112
REGγ has been shown to promote the polyubiquitination of
p53 in a proteasome binding-independent manner (Zhang and
Zhang, 2008). We therefore wanted to evaluate whether
REGγ overexpression modified the polyubiquitination
state of ARQ112. We observed that the overexpression of
both REGγ and REGγP245Y significantly decreased the
polyubiquitination state of ARQ112 (Figure 6). While the
total amount of ubiquitin pulled down from the lysates
was equivalent across cell lines (data not shown), the
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FIGURE 5 | Overexpression of REGγ and mutant REGγP245Y fail to
protect PC12 ARQ112 cells from DHT-dependent death.
(A,B) ARQ10 and ARQ112 cells with and without stable expression of REGγ
or REGγP245Y were cultured in the presence or absence of DHT for 12 days.
Cells were stained with trypan blue, 200 cells were counted in triplicate, and
the percentage of dead cells (trypan blue-positive) was calculated. Data are
representative of more than three independent experiments. Statistical
analysis was carried out using two-factor ANOVA with post hoc Tukey HSD for
individual comparisons. ∗∗p < 0.01; ∗∗∗p < 0.001.
amount of polyubiquitinated ARQ112 was reduced in
cells expressing either REGγ or REGγP245Y. Therefore,
REGγ negatively impacts ARQ112 polyubiquitination. The
apparent decrease in ARQ112 polyubiquitination might be
explained by increased ARQ112 aggregation and consequent
insolubility. However, evaluation of ARQ112 polyubiquitination
was carried out under conditions that minimized AR
aggregation; indeed, no AR-containing nuclear inclusions
were observed in the short time of DHT treatment (data
not shown). Moreover, we evaluated AR solubility using
ultracentrifugation and Western blot analysis; no increase in
ARQ112 sedimentation was observed under these conditions.
Consistent with its lack of interaction with ARQ10, REGγ had
no effect on the polyubiquitination state of ARQ10 (data not
shown).
We next wanted to evaluate the mechanism by which
REGγ decreases the polyubiquitination of ARQ112. A recent
study showed that REGγ facilitates the interaction of the
E3 ubiquitin ligase MDM2 with p53, thus promoting the
polyubiquitin-dependent degradation of p53 (Zhang and
Zhang, 2008). MDM2 is a known E3 ubiquitin ligase for
the AR (Lin et al., 2002); therefore, we hypothesized that
FIGURE 6 | Overexpression of REGγ and REGγP245Y decreases the
polyubiquitination state of ARQ112. PC12 ARQ112 cells were induced
with Dox for 48 h, and then treated for an additional 12 h with Dox, DHT and
epoxomycin. Cells were harvested in tandem ubiquitin binding entity (TUBE)
cell lysis buffer and treated with GST-TUBE2. TUBE assay protocol was
carried out and the eluate was evaluated by Western analysis using anti-AR
antibody AR(441) to detect polyubiquitinated ARQ112 (left). Densitometry was
performed and the ratio of polyubiquitinated AR to WCE normalized AR
monomer (right) was calculated.
FIGURE 7 | Overexpression of REGγ decreases ARQ112 interaction
with MDM2. PC12 ARQ112 cells stably overexpressing REGγ or
REGγP245Y were induced with Dox for 48 h and treated with DHT and
epoxomycin for the last 15 h. Protein lysates were harvested at 48 h and then
AR was co-immunoprecipitated with AR(H280) antibody (left). Protein
complexes were evaluated via Western blot analysis using AR(441), REGγ and
MDM2 antibodies. (Right) Western blots of whole cell lysates (WCE) used for
IP were probed with antibodies detecting REGγ, AR (AR(318)), MDM2 and
γ-tubulin.
REGγ might prevent the interaction of ARQ112 with MDM2,
resulting in reduced polyubiquitination of the receptor.
We observed MDM2 co-immunoprecipitation with polyQ-
expanded AR only in the presence of the proteasome
inhibitor epoxomycin (Figure 4B), which substantially
increased the otherwise low levels of MDM2 in these
cells (Figure 4B, right). Consistent with our finding that
REGγ overexpression decreased AR polyubiquitination,
we found that REGγ overexpression also decreased the
interaction of ARQ112 with MDM2 (Figure 7), suggesting
that REGγ may decrease ARQ112 polyubiquitination by
reducing the interaction of ARQ112 with the ubiquitin ligase
MDM2.
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FIGURE 8 | REGγ and REGγK188E overexpression rescued motor neurons from DHT-dependent death, while REGγP245Y overexpression did not.
(A) Dissociated spinal cord cultures from ARQ112 transgenic mouse embryos were cultured for 3 weeks. Cultures were infected with adeno-associated virus (AAV)
expressing REGγ, REGγK188E or EGFP for 5 days and then treated with or without DHT for 7 days. Cultures were immunostained with FLAG antibody to detect
FLAG-REGγ and FLAG-REGγK188E infected cells, with an antibody against neurofilament heavy chain (SMI32) to reveal motor neurons and stained with Hoechst for
nuclei. Arrow indicates a motor neuron infected with nuclear FLAG-REGγ. (B) Left, motor neurons from immunostained cultures in (A) were counted in 10 random
fields (2 wells per condition). Two factor ANOVA with post hoc TUKEY HSD was performed. The difference in the number of motor neurons between the +DHT and
–DHT conditions for EGFP was not statistically significant (p = 0.05). Note, however, the complete lack of cell death in the REGγ- and REGγK188E- expressing
cultures. Right, protein lysates from the above cultures were evaluated by Western blot for REGγ and GAPDH (loading control). (C) Left, motor neurons were infected
with EGFP, FLAG-REGγ and FLAG-REGγP245Y expressing AAV for 5 days and treated with or without DHT for 7 days. Cultures were immunostained with
SMI32 antibody and motor neurons in 10 random fields in each of three wells per condition were counted. Two factor ANOVA with post hoc TUKEY HSD was
performed. ∗∗p < 0.01. Right, protein lysates were evaluated by Western blot with AR(H280), REGγ and γ-tubulin antibodies.
Overexpression of REGγ and REGγK188E
Protects Transgenic SBMA Motor Neurons
from DHT-Dependent Cell Death
Our finding that REGγ overexpression in PC12 cells
significantly increased ARQ112 aggregation led us to ask
whether REGγ overexpression would impact SBMA motor
neuron survival. Transgenic ARQ112 motor neurons undergo
significant hormone-dependent death (Montie et al., 2009,
2011; Orr et al., 2010; Heine et al., 2015; Zboray et al., 2015).
We hypothesized, based on our observations in PC12 cells,
that overexpression of REGγ and REGγK188E might enhance
motor neuron death after exposure to hormone. To test
this hypothesis, we infected dissociated spinal cord cultures
with AAV that expressed FLAG-REGγ isoforms. A high
percentage of motor neurons were infected (Figure 8A), and
significant overexpression of REGγ isoforms was observed
(Figure 8B, right). In contrast to our observations in PC12 cells,
however, we found that overexpression of either REGγ or
REGγK188E not only failed to enhance DHT-dependent
toxicity, but rather rescued ARQ112 motor neurons from
DHT-induced toxicity (Figure 8B, left). Moreover, REGγ
protected ARQ112 motor neurons from DHT-dependent
toxicity in a proteasome binding-dependent manner, as
overexpression of the proteasome non-binding mutant
REGγP245Y did not rescue motor neuron viability (Figure 8C).
This suggests that the effect of REGγ on motor neuron survival
depends on a REGγ proteasome binding (11S)-dependent
mechanism.
We next determined whether REGγ overexpression rescued
motor neurons fromDHT-dependent cell death by altering levels
of the mutant polyQ-expanded AR. Western analysis revealed
that REGγ overexpression did not alter AR monomer levels
(Figure 8C, right), suggesting that REGγ does not promote
motor neuron survival by enhancing ARQ112 degradation. The
effect of REGγ on AR aggregation and inclusion formation
in cultured motor neurons could not be evaluated, as
inclusions do not form in these neurons during the time
course of the toxicity assays performed here (Heine et al.,
2015).
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FIGURE 9 | REGγ effects may be mediated by the splicing factor SC35.
(A) SC35 levels are increased in the presence of DHT in PC12 cells expressing
ARQ112. REGγ overexpression ameliorates enhanced SC35 levels in a
manner dependent upon its ability to bind the proteasome. PC12 cells
expressing ARQ10, ARQ112 and ARQ112 + REGγ and ARQ112 + REGγ
(P245Y) were treated with EtOH or DHT for 48 h, harvested and Western
analysis was performed to determine SC35 levels. (B) Knockdown of
SC35 rescues PC12 cells expressing ARQ112 from DHT-dependent death.
(Continued)
FIGURE 9 | Continued
PC12 cells expressing ARQ112 were stably (bulk) transfected with plasmids
containing scrambled miRNA or two miRNAs against SC25 (#24 and #27) and
treated with EtOH or DHT for 12 days, after which cell death was assessed by
trypan blue exclusion. SC35 #24 miRNA = 21% knockdown, SC35
#27 miRNA = 30% knockdown, SC35 #24 + 27 miRNA = 40% knockdown.
Two factor ANOVA with post hoc TUKEY HSD was performed. ∗∗p < 0.01;
∗∗∗p < 0.001. See Supplementary Figure S2 for representative images used
for SC35 quantification. (C) Knockdown of SC35 rescues primary motor
neurons expressing ARQ112 from DHT dependent death. Dissociated spinal
cord cultures from ARQ112 transgenic mouse embryos were cultured for
3 weeks. Cultures were infected with AAV expressing scrambled miRNA or
miRNA against SC35 (#27) for 5 days and then treated with EtOH or 10µM
DHT for 7 days. Cultures were immunostained with an antibody against
neurofilament heavy chain (SMI32) to reveal motor neurons and stained with
Hoechst for nuclei. Green fluorescence revealed the motor neurons that were
infected with AAV, as the miRNA constructs are tagged with EmGFP.
Infectivity, scrambled = 75%, miRNA against SC35 (#27) = 77%. Two factor
ANOVA with post hoc TUKEY HSD was performed. ∗∗p < 0.01; n.s., not
statistically significant.
REGγ Effects May be Mediated by the
Splicing Factor SC35
The observation that the neuroprotection conferred by
REGγ in SBMA mouse motor neurons requires its ability
to bind the 20S proteasome core prompted us to evaluate
potential REGγ substrates that mediate its effects. Several
REGγ-activated proteasomal substrates have been identified.
These include the CDK inhibitors p21WAF/CIP1, p16INK4a and
p19ARF (Chen et al., 2007) the transcriptional co-activator
SRC-3 (Li et al., 2006) and the E3 ligase SMURF1 (Nie
et al., 2010). We evaluated levels of p16INK4a in motor
neurons in the presence of overexpressed REGγ but
found no change in its levels (unpublished data). Another
potential substrate of REGγ-capped proteasomes is the
nuclear splicing factor SC35. REGγ-capped proteasomes
colocalize with SC35-containing nuclear speckles (Baldin
et al., 2008). Moreover, knockdown of REGγ leads to
altered SC35 distribution. To evaluate the potential role of
SC35 in REGγ-induced protection of SBMA motor neurons,
we first determined the effect of ARQ112 expression on
SC35 levels, using the PC12 cell model described above.
SC35 is transcriptionally regulated by E2F1 ( Merdzhanova
et al., 2008) and is consequently present at much higher (and
detectable) levels in cycling PC12 cells than in primary motor
neurons (unpublished data). Expression of polyQ-expanded
AR resulted in increased expression of SC35, which was
further increased by DHT treatment (Figure 9A). Moreover,
overexpression of REGγ, but not the proteasome binding-
mutant REGγ-P245Y, resulted in the reduction in SC35 levels
(Figure 9A).
To determine the extent to which decreased SC35 levels
contributed to REGγ neuroprotection, we knocked down
SC35, in the absence of overexpressed REGγ and determined
the effect on cellular viability. ARQ112-expressing PC12 cells
were stably transfected with either a plasmid expressing
scrambled miRNA or a plasmid expressing miRNA against
SC35 and placed under blasticidin selection for 2 weeks;
after 2 weeks, all cells were confirmed to express EmGFP,
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which is contained on the same expression plasmid. Cells
were then treated with EtOH or DHT and viability assessed
after 12 days. Reducing SC35 expression provided complete
protection against DHT-dependent death (Figure 9B).
To determine if knockdown of SC35 would also prevent
DHT-dependent ARQ112 toxicity in primary motor neurons
derived from SBMA transgenic mice, we infected dissociated
spinal cord cultures from ARQ112-expressing mice with
AAV expressing either a scrambled miRNA or a miRNA
against SC35 and evaluated the effect on DHT-dependent
AR toxicity. Knockdown of SC35 in primary SBMA motor
neurons also substantially reduced DHT-dependent AR toxicity
(Figure 9C).
DISCUSSION
The role of nuclear degradative processes in polyQ diseases
has garnered much interest since the discovery of nuclear
inclusions. In SBMA, in particular, in which the site of
pathogenesis is the nucleus (Takeyama et al., 2002; Montie
et al., 2009; Nedelsky et al., 2010), identifying the role of
nuclear proteases in the inefficient degradation and aggregation
of the mutant AR may be critical to understanding the
disease process. PolyQ-expanded AR displays altered nuclear
metabolism; while it is able to transactivate target genes, at
some point in its nuclear metabolism, it misfolds and forms
nuclear inclusions that consist of amino-terminal fragments
(Li et al., 1998; Walcott and Merry, 2002; Li M. et al.,
2007; Heine et al., 2015). Nuclear inclusions also contain
molecular chaperones, ubiquitin, and proteasomal subunits
such as the 20S proteasome core and REGγ, a nuclear
proteasomal activator (Li et al., 1998; Stenoien et al., 1999;
Abel et al., 2001; Bailey et al., 2002). This finding suggested
that REGγ might play a role in mutant AR metabolism
and led us to further explore the role of REGγ in SBMA
pathogenesis.
Our entrée into this question focused on the restricted
proteasomal catalytic activity that is induced by nuclear
REGγ (Realini et al., 1997), and we hypothesized that
this feature contributes to the inefficient proteasomal
degradation of nuclear AR. However, we found that the
overexpression of both REGγ and REGγK188E not only
increased, rather than decreased, ARQ112 aggregation in
PC12 cells, but that this effect of REGγ on aggregation
is independent of the manner in which it activates the
proteasomal core. Consistent with this observation, REGγ
(P245Y), which is unable to bind to the 20S proteasome core,
also increased ARQ112 aggregation, implicating a mechanism
that is independent of REGγ’s role as an 11S proteasomal
activator.
Our studies here identified one proteasome binding-
independent mechanism of REGγ, which may impact
ARQ112 aggregation, as its inhibition of MDM2 binding
to the mutant AR. We focused on MDM2 in our studies,
as MDM2 can polyubiquitinate normal AR (Lin et al.,
2002) and because REGγ had been shown to modify
MDM2 binding to another MDM2 substrate, p53 (Zhang
and Zhang, 2008). We found that MDM2 interacts with
expanded ARQ112 and that REGγ overexpression decreased
this interaction; preliminary findings also suggest that it
decreases ARQ112 interaction with E6AP, another known AR
E3 ligase (data not shown). The fact that multiple E3 ligases
may be impacted by REGγ is notable, as E3 ubiquitin ligases
may act redundantly to promote the degradation of poly-Q
expanded proteins such as AR and ataxin-3 (Morishima
et al., 2008). Further studies will be needed to determine
if the decrease in ARQ112 interaction with E3 ligases is
responsible for the decrease in ARQ112 polyubiquitination.
It is also possible that REGγ may promote the degradation
of E3 ubiquitin ligases involved in AR degradation, since
a recent study showed that REGγ is capable of interacting
with and promoting the degradation of the E3 ubiquitin
ligase Smurf1 (Nie et al., 2010); of note, however, no
effect of REGγ on MDM2 levels was observed (Figure 7,
right).
Whether and how such a decrease in AR polyubiquitination
plays a role in its increased aggregation is unknown. Our
finding that REGγ decreases expanded AR polyubiquitination
predicts that it would increase expanded AR half-life. Although
we found no effect of REGγ on steady-state levels of
monomeric AR (Figures 3B, 7) or on AR half-life (data
not shown; evaluated prior to its aggregation), it may be
that REGγ interacts with a subset of AR protein, impacting
its degradation and thus overall aggregation and toxicity.
Identifying such an AR subpopulation is the subject of ongoing
studies.
To study the effect of REGγ on toxicity in motor neurons,
we utilized transgenic motor neurons derived from a mouse
model of SBMA (Mojsilovic-Petrovic et al., 2009; Montie
et al., 2009, 2011; Orr et al., 2010; Heine et al., 2015; Zboray
et al., 2015). These mice develop the slowly progressive motor
deficits and pathology seen in SBMA patients (Chevalier-
Larsen et al., 2004). Our finding that REGγ, REGγK188E, and
REGγP245Y increased mutant AR aggregation in PC12 cells
predicted that the increased expression of REGγ isoforms
would promote DHT-dependent motor neuron death. To our
surprise, we found that both REGγ and REGγK188E rescued
motor neurons from DHT-dependent death. Moreover, this
rescue occurred in a proteasome binding-dependent manner,
as REGγP245Y failed to protect motor neurons from AR
toxicity.
REGγ has been previously shown to increase the viability
of mutant huntingtin (Htt)-expressing striatal neurons after
exposure to cell stressors (Seo et al., 2007). Thus, REGγ
can enhance the survival of distinct neuronal populations
in two models of polyQ disease. How REGγ promotes
neuronal survival is unknown. We found that REGγ
does not promote motor neuron survival by enhancing
ARQ112 degradation. Instead, REGγ may increase the
destruction of other substrates involved in the pathogenesis
of polyQ disease, leading to enhanced neuronal viability. We
found that SC35, which is altered by REGγ knockdown and
is present in nuclear speckles along with active REGγ-capped
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11S proteasomes (Baldin et al., 2008), is increased upon
DHT-treatment of polyQ-expanded AR-expressing PC12 cells
and reduced by REGγ, but not REGγ-P245Y, expression.
Moreover, reducing SC35 levels in both PC12 cells and
motor neurons rescued both cell types from DHT-dependent
toxicity.
Our studies of REGγ on ARQ112 toxicity revealed distinct
effects on PC12 cells and motor neurons. We propose
that REGγ is involved in competing proteasome binding-
dependent and -independent pathways. The proteasome
binding-dependent REGγ pathway is predominant in motor
neurons and is neuroprotective. In contrast, the proteasome
binding-independent REGγ pathway predominates in PC12 cells
and promotes AR aggregation and toxicity. Consistent with
this view, REGγP245Y overexpression promoted AR toxicity
in PC12 cells, while it failed to protect motor neurons from
DHT-dependent toxicity. The distinct effects of REGγ in
PC12 cells and transgenic motor neurons are in contrast with
the common neuroprotective effect of SC35 knockdown in both
cell types. It may be that the interaction of ARQ112 with
REGγ reduces the nuclear levels of REGγ-capped 11S
proteasomes. Increasing levels of REGγ in motor neurons
may be sufficient to restore 11S proteasome degradative
capacity, thus reducing the levels of key 11S proteasome
substrates, including SC35. However, the higher levels of
SC35 in cycling PC12 cells may not be sufficiently reduced by
REGγ overexpression, shifting the balance of REGγ effects to
one of proteasome binding-independent interaction with the
mutant AR.
A previous study tested the hypothesis that REGγ knockdown
would improve phenotype in HD R6/2 mice. However, the
knockout of REGγ had no effect on HD disease progression or
formation of nuclear inclusions (Bett et al., 2006). While the
site of SBMA pathogenesis is clearly restricted to the nucleus,
in HD, pathogenic mechanisms likely involve both the nucleus
and cytoplasm. An effect of REGγ, a nuclear protein, might be
diluted by a cytoplasmic disease mechanism. Moreover, based
on our findings that REGγ protects motor neurons expressing
mutant AR, we predict that the knockout of REGγ would
exacerbate disease; whether this could be observed in the severe
R6/2 model of HD is unknown. Our findings of REGγ protection
of motor neurons predict that overexpressing REGγ rather than
knocking it down, would improve polyQ expansion disease
phenotype, not only for SBMA but for other polyQ repeat
diseases as well.
The observed rescue of motor neurons from DHT toxicity
by REGγ, in a proteasome binding-dependent manner,
predicts that the composition of nuclear proteasomes was
altered by its overexpression. Native PAGE analysis of
PC12 nuclear fractions failed to reveal such a difference
(data not shown). However, given the limited abundance
of nuclear proteasomes, it is likely that native PAGE
lacks the necessary sensitivity to reveal such changes.
Also, REGs are in rapid equilibrium with proteasomes
(Welk et al., 2016), making such measurements of
proteasomal composition difficult to determine with accuracy.
Nonetheless, we predict that REGγ overexpression increases
11S-containing proteasomes, thus enhancing the degradation
of 11S proteasomal substrates involved in motor neuron
death.
In conclusion, these studies indicate that REGγ is involved
with polyQ-expanded AR metabolism through two distinct
mechanisms. In its proteasome binding-independent role,
REGγ decreases the interaction of ARQ112 with E3 ubiquitin
ligases, leading to a reduction in mutant AR polyubiquitination
and promoting its aggregation and toxicity in PC12 cells. By
contrast, REGγ promotes motor neuron viability through a
proteasome binding-dependent mechanism, likely involving
increased levels of 11S proteasomes and leading to the
degradation of 11S proteasomal substrates, potentially
including SC35. These findings suggest a model in which
mutant AR binding to REGγ in transgenic motor neurons
reduces its activation of 11S proteasomes and leads to
increased levels of 11S proteasomal substrates. We predict
that therapies directed at enhancing the role of REGγ
in 11S-proteasome degradation may prove beneficial in
preventing toxicity in SBMA and other polyQ diseases.
Additional studies are essential to fully understand the
mechanism by which REGγ proteasome binding promotes
motor neuron viability, as well as to further comprehend
how the alternative roles of REGγ degradation affect
nuclear metabolism in the context of neurodegenerative
diseases.
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